|Revised response criteria for malignant lymphoma|
BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ...
Journal of clinical oncology 25 (5), 579-586, 2007
|A prognostic score for advanced Hodgkin's disease|
D Hasenclever, V Diehl, JO Armitage, D Assouline, M Björkholm, ...
New England Journal of Medicine 339 (21), 1506-1514, 1998
|Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage …|
A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ...
Journal of clinical oncology 25 (24), 3746-3752, 2007
|FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma|
M Hutchings, A Loft, M Hansen, LM Pedersen, T Buhl, J Jurlander, S Buus, ...
Blood 107 (1), 52-59, 2006
|Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial|
J Overgaard, HS Hansen, L Specht, M Overgaard, C Grau, E Andersen, ...
The Lancet 362 (9388), 933-940, 2003
|Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis|
P Warde, L Specht, A Horwich, T Oliver, T Panzarella, M Gospodarowicz, ...
Journal of clinical oncology 20 (22), 4448-4452, 2002
|A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish …|
J Overgaard, HS Hansen, M Overgaard, L Bastholt, A Berthelsen, ...
Radiotherapy and Oncology 46 (2), 135-146, 1998
|Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)|
L Specht, J Yahalom, T Illidge, AK Berthelsen, LS Constine, HT Eich, ...
International Journal of Radiation Oncology* Biology* Physics 89 (4), 854-862, 2014
|Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines|
T Girinsky, R van der Maazen, L Specht, B Aleman, P Poortmans, ...
Radiotherapy and Oncology 79 (3), 270-277, 2006
|Osteoradionecrosis of the jaws: clinical characteristics and relation to the field of irradiation|
JJ Thorn, HS Hansen, L Specht, L Bastholt
Journal of Oral and Maxillofacial Surgery 58 (10), 1088-1093, 2000
|Surveillance following orchidectomy for stage I seminoma of the testis|
H von der Maase, L Specht, GK Jacobsen, A Jakobsen, EL Madsen, ...
European journal of cancer 29 (14), 1931-1934, 1993
|Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma|
M Hutchings, A Loft, M Hansen, LM Pedersen, AK Berthelsen, S Keiding, ...
Haematologica 91 (4), 482-489, 2006
|Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3 …|
L Specht, RG Gray, MJ Clarke, R Peto
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 1998
|Breathing adapted radiotherapy for breast cancer: comparison of free breathing gating with the breath-hold technique|
SS Korreman, AN Pedersen, TJ Nøttrup, L Specht, H Nyström
Radiotherapy and oncology 76 (3), 311-318, 2005
|Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold|
AN Pedersen, S Korreman, H Nyström, L Specht
Radiotherapy and oncology 72 (1), 53-60, 2004
|Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography–staged treatment-naive patients with Hodgkin lymphoma|
TC El-Galaly, F d'Amore, KJ Mylam, P de Nully Brown, M Bøgsted, A Bukh, ...
Journal of clinical oncology 30 (36), 4508-4514, 2012
|Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents, and time from chemotherapy|
J Pedersen-Bjergaard, SO Larsen, J Struck, HH Hansen, L Specht, ...
The Lancet 330 (8550), 83-88, 1987
|Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial|
MPE André, T Girinsky, M Federico, O Reman, C Fortpied, M Gotti, ...
J Clin Oncol 35 (16), 1786-1794, 2017
|The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer|
CB Lajer, E Garnaes, L Friis-Hansen, B Norrild, MH Therkildsen, M Glud, ...
British journal of cancer 106 (9), 1526-1534, 2012
|Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials|
J Franklin, A Pluetschow, M Paus, L Specht, AP Anselmo, A Aviles, G Biti, ...
Annals of Oncology 17 (12), 1749-1760, 2006